The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Selecting the appropriate first-line therapeutic approach for patients with MZL
Izidore Lossos, MD, University of Miami, Miami, FL, underlines the three sub-entities of marginal zone lymphoma (MZL) and stresses the importance of recognizing the differences between them to guide appropriate treatment strategies. Dr Lossos considers bendamustine combined with rituximab (BR), radiation therapy, and rituximab monotherapy as potential treatment options, depending on the specific MZL subtype. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
